/
HALO
$78.43+$1.25 (+1.62%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.9B
119M shares
52-week range
$51.06 – $82.22
88% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$32.07
Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
www.halozyme.com- Employees
- 423
- IPO / List date
- Mar 12, 2004
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds HALO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 731,811 | $47.3M |
| Bridgewater Associatesas of 2026-03-31 | 511,429 | $33.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HALO yet.
